We are facing a disturbing paradox in science. We have unprecedented potential for advancements spurred by current technologies. But at the same time we are confronting flat to declining funding.
The Orphan Drug ImbroglioThe controversy over HRSA's authority emerged late last year, when the agency published a legislative rule that sought to provide coverage for some uses of orphan drugs.
Many people love the 340B Drug Pricing Program.
